This article discusses current obstacles to the rapid development of safe and effective treatments for rare cancers, and considers measures required to overcome these challenges. In order to develop novel clinical options for rare cancers, which tend to remain left out of novel therapeutic development because of their paucity, efficient recruitment of eligible patients, who tend to be widely dispersed across the country and treated at different centers, is necessary. For this purpose, it is important to establish rare cancer registries that are linked with clinical studies, to organize a central pathological diagnosis system and biobanks for rare cancers, and to consolidate patients with rare cancers to facilities that can conduct clinical studies meeting international standards. Establishing an all-Japan cooperative network is essential. Clinical studies of rare cancers have considerable limitations in study
design and sample size as a result of paucity of eligible patients and, as a result, the level of confirmation of the efficacy and safety shown by the studies is relatively low. Therefore, measures to alleviate these weaknesses inherent to external conditions need to be explored. It is also important to reform the current research environment in order to develop world-leading treatment for rare cancers, including promotion of basic research, collaboration between industry and academia, and improvement of the infrastructure for clinical studies. Collaboration among a wide range of stakeholders is required to promote the clinical development of treatment for rare cancers under a nationwide consensus.
K E Y W O R D S
cancer registry, evaluation method, rare cancer, rare subtype of cancer, therapeutic development
| INTRODUCTION
A rare cancer is defined as a cancer with an approximate morbidity (incidence) of <6 per 100 000 population, which has more unsolved clinical and therapeutic problems compared to other cancers because of the limited number of patients. 1 As for actual clinical practice for rare cancers in Japan, as a limited number of patients are dispersed across the country and treated at different sites in different clinical areas, the patients have difficulty in receiving the newest evidence-based treatment at the right time and clinical studies are difficult to promote. 2 Development of guidelines for rare cancers also tends to be delayed compared to more common cancers and, as a result, treatment satisfaction and performance in patients with rare cancers have been reported to be poorer than those in patients with more common cancers. 3 However, even among more common cancers, rare variants characterized by specific molecular abnormalities have been identified through recent dramatic advances in genomic analysis technology. As a result, cancers that have not previously been considered to be rare are now regarded as an assembly of rare subtypes of cancer based on different molecular abnormalities. If each of these rare subtypes required specific diagnosis, treatment and therapeutic development, the limited number of patients would lead to problems similar to those for rare cancers.
Although Guidance on the Clinical Development of Ultra-orphan 
OF CANCER
In this article, we broadly discuss rare cancers, which are defined as both rare cancers in the narrow sense and rare subtypes of cancer.
The former is narrowly defined as an anatomically and clinicopathologically recognized cancer that occurs rarely (approximate morbidity of <6 per 100 000 population) in accordance with the report of the Investigation Committee on the Desirable State of Medical Treatment and Support for Rare Cancers 1 described above.
A rare subtype of cancer is defined as a rare disease entity extracted through identification of a specific molecular abnormality in an anatomically and clinicopathologically recognized cancer entity. [8] [9] [10] Although rare cancers and rare subtypes of cancer are both rare disease groups with a limited number of patients, in some respects, they have different clinicopathological backgrounds and require different considerations in terms of drug development and implementation of clinical studies (Table 1) .
| PATHOLOGICAL DIAGNOSIS AND BIOBANK FOR R ARE CANCERS
Accurate pathological diagnosis is absolutely fundamental to treatment/research of rare cancers including clinical studies. However, questions have been raised about the accuracy of pathological diagnosis for rare cancers because of their intrinsically unusual nature, shortage of expert pathologists, and the paucity of pathologists experienced in the relevant cancer type at each institution.
For example, the rate of diagnostic agreement for sarcomas, representative rare cancers, between expert and non-expert pathologists has been reported to be 50%-70% overseas, causing therapeutically significant diagnostic disparity in 10%-20% of cases. 11, 12 In Japan, the accuracy of such pathological diagnoses in a routine clinical setting has not been validated.
One way to address these diagnostic problems related to rare cancers is to establish a central diagnostic system for rare cancers to be shared by medical institutions throughout the country, thereby improving diagnostic accuracy and facilitating required molecular biological analyses such as next-generation sequencing.
To meet this goal, specific approaches should be considered, including the linking of human resources and organizations virtually through the internet, and reforming the centralization structure without disrupting the existing one, rather than attempting to centralize human resources and organizations. Such reform of the diagnostic system would be expected to encourage and facilitate enrolment of patients into registries of rare cancers, and also into appropriate clinical studies.
Moreover, because the relationship between genomic information and therapeutic efficacy/clinical course remains poorly understood in rare cancers, archiving of biological samples (biobank) aimed at future research or therapeutic development is essential. Use of a reinforced national pathological diagnostic system for organization of such rare cancer biobanks represents another important concern.
| RARE CANCER REGISTRY
To initiate clinical studies of rare cancers, eligible patients with rare cancers who are widely dispersed across the country and treated at different centers must be efficiently recruited at study sites. For this purpose, an all-Japan patient referral system that extends beyond individual facilities would be needed.
This approach would require information about the patients with rare cancers who are treated at each institution. Such information would need to have real-time immediacy (and also interactivity), in contrast to so-called epidemiological registries. A system different from that used for population-based epidemiological registries would be essential for registries for clinical studies of rare cancers.
However, registries for rare cancers are expected to be used not only for patient recruitment into clinical studies but also as an external source of control data. If it becomes possible to leverage external control data by using the registry, the burden associated with assessment of a new drug in clinical studies of rare cancers, which are ill-fitted with comparator-based efficacy assessment, would also be reduced.
An example of a recent approach in Japan for addressing this problem includes the MASTER KEY Project, which has been comprehensively collecting genetic and treatment information and prognostic data for patients with rare cancers to create a large-scale basic database that can be applied to clinical studies. 13 Case registration for rare subtypes of cancer has also been started through SCRUM-Japan, a genomic screening project for lung cancer and gastrointestinal cancer, which has been founded by more than 10 pharmaceutical companies and organized by National Cancer Center. 14 The MASTER KEY Project and SCRUM-Japan are both oriented to construction of a large-scale patient registry of rare cancers and rare subtypes that integrates clinical and genomic information. This research is expected to establish globally compatible rare cancer genomic data registries that could cover future global trials.
| CLINICAL STUDIES OF RARE CANCERS
In clinical studies of rare cancers, study design is considerably restricted as a result of the paucity of patients, compared to clinical T A B L E 1 Rare cancers and rare subtypes of cancer Rare cancers in the narrow sense Rare subtypes of cancer Definition A cancer that has been recognized as an entity anatomically and clinicopathologically, which occurs rarely (approximate morbidity of <6 per 100 000 population).
A rare disease group extracted through identification of a common molecular abnormality from among a cancer type that is anatomically and clinicopathologically recognized as an entity.
Disease examples Soft tissue sarcoma, osteosarcoma, ocular malignancy, small intestinal cancer, neuroendocrine tumor, central nervous system glioma etc.
Rare fractions of lung adenocarcinoma: ALK gene translocation (5%), RET fusion gene (1%), ROS1 gene translocation (1%), and BRAF mutations (1%) etc.
Characteristics
• In many cases, the molecular abnormality characterizing each rare cancer type is absent or remains unknown • It is difficult to expect that a drug targeting a single molecule would show marked therapeutic efficacy • The physician or the department in charge may not always be specialized in cancer treatment • In order to improve the quality of clinical practice and promote clinical research, measures including consolidation and networking are considered to be effective In the EU and USA, discussions are held at various forums to promote development of pharmaceutical products for rare diseases including cancers. For example, Rare Cancers Europe (RCE) initiative presented considerations for clinical study design and alternative endpoints for rare cancers. 15 The International Rare Cancers Initiative (IRCI) has highlighted characteristic approaches used in previous clinical studies of relevant rare cancers, and proposed that a study should be regarded as a "Phase III study" if it is meant to be definitive or practice-changing, despite weakness of the trial design. 16 It is important to actively discuss and implement measures to In addition, for regulatory approval of these products, it is important to actively transmit information to society and obtain understanding regarding the presence of disadvantages associated with the approval based on limited information (that the efficacy and safety are not highly reliable), even though there may be major advantages, especially in the field of life-threatening cancer, of prompt delivery of pharmaceutical products. It must be said that there is no completely correct answer for the development and assessment of pharmaceutical products.
T
Study design Outline of the design
Umbrella study A method in which a clinical study platform (umbrella) with genomic analysis for patient selection is constructed, and the patients are assigned to multiple arms (rare fractions) according to actionable driver mutations and receive a matched molecular targeting drug in order to assess them simultaneously. Examples include NCI-MATCH by the NCI in USA Basket study A method in which patients with common actionable driver mutations across organs (rare fractions of each organ cancer) are collected to promote the development of a drug corresponding to the relevant genomic abnormality. The aim is to obtain a therapeutic indication across organs based on a specific genomic abnormality. Examples include a clinical study of BRAF inhibitor in cancers with BRAF mutations and a clinical study of an immune checkpoint inhibitor for cancers with abnormalities in DNA repair (microsatellite instability-positive: MSI-H or dMMR).
N-of-1 study A study in which multiple treatments are applied to 1 patient at different times to compare the effects of these treatments.
Although an assessment can be made in a small number of subjects (rare cancers, rare fractions) by comparing the treatments in the same individual (under the same conditions), it has limitations similar to those of a cross-over study
Adaptive design A study design in which specific factors are changed based on the data obtained during the study, as planned in advance (selection of dose groups, change in the probability of assignment to a specific treatment group, change in the sample size etc.)
Bayesian design An assessment can be carried out with a relatively small number of subjects by introducing a prior distribution that represents biological findings and/or data of previous research to a parameter such as therapeutic efficacy etc. Unlike conventional statistical inference (hypothesis testing and confidence interval by the frequentist approach), consistent inference procedures and criteria on therapeutic efficacy may be applied consecutively across analysis time points (without adjustment for the multiplicity of analysis), based on the posterior distribution combining the prior distribution and study data. It can also be applied to umbrella, basket, or Nof-1 studies, as well as those with adaptive designs 
| iPS cells
Rare diseases can be the target of development of pharmaceutical products using the characteristics of iPS cells. The development of pharmaceutical products for rare diseases is associated with many difficulties including a paucity of pathological and biological data of relevant diseases and uncertainty about returns from investment for the research and development. In this context, there are high expectations that iPS cell technology will be able to overcome these difficulties. 20 Fibrodysplasia ossificans progressiva is a very rare genetic disease characterized by generalized heterotopic ossification that progresses from childhood. It is caused by missense mutations in the ACVR1/ALK2 gene coding the bone morphogenetic protein (BMP)
receptor, although the pathological mechanism is not known. As a characteristic of this disease, resection of the lesion exacerbates the symptoms and thus it is difficult to collect research materials. Toguchida et al overcame this problem by deriving pathologically responsible cells from iPS cells established from the peripheral blood of a patient. As a result, they discovered that an unexpected molecular mechanism, induction of heterotopic ossification by activin-A, was responsible for the disease and, furthermore, based on these findings, they succeeded in identifying rapamycin as a drug with potential therapeutic application. 21, 22 Clarification of the pathology of rare cancers and subsequent therapeutic development are associated with many difficulties: (i) difficulty obtaining clinical samples as a result of disease rarity; (ii) delayed study of the disease as a result of its rarity and inability to proceed to development of a therapeutic agent because the pathological mechanism is unknown; and (iii) difficulty in conducting studies to validate efficacy and safety etc. These difficulties can be overcome with iPS cells. An inexhaustible supply of iPS cells that can replace difficult-to-obtain clinical samples is expected to make an enormous contribution to a variety of aspects including elucidation of the pathology of rare cancers, screening of candidate drugs, and conducting clinical studies to validate efficacy/safety. 
| FUTURE PERSPECTIVES
We reviewed some concerns related to therapeutic development for rare cancers that should be addressed, clarifying the definition of rare cancers.
The first concern is the development of an efficient structure for treatment and clinical research of rare cancers. As patients will be disadvantaged by the absence of accurate pathological diagnosis, there is an urgent need to improve the accuracy of pathological diagnosis of rare cancers. In the field of rare cancers, it is also partic- Products, and Cosmetics. 28 In addition, a new approval system for regenerative medicine, including conditional approval, was started in line with the practical application of regenerative medicine. In October 2017, a conditional early approval system was also started for pharmaceutical products. 
